Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD)

Vaccine

Volumn 32, Issue 44, 2014, Pages 5769-5775

  Seligman, Stephen J ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Risk groups; Vaccine; Viscerotropic; Yellow fever

Indexed keywords

YELLOW FEVER VACCINE;

AUTOIMMUNE DISEASE; CLINICAL EVALUATION; DISEASE PREDISPOSITION; DISEASE SURVEILLANCE; FAMILY; GENE MUTATION; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; INCIDENCE; MORTALITY; OUTCOME ASSESSMENT; REVIEW; SEX DIFFERENCE; THYMOMA; TROPICAL DISEASE; YELLOW FEVER VACCINE ASSOCIATED VISCEROTROPIC DISEASE; ADULT; ADVERSE DRUG REACTION; CHILD; COMPLICATION; DRUG SURVEILLANCE PROGRAM; FEMALE; INFANT; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RISK; RISK FACTOR; THYMUS; YOUNG ADULT;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AUTOIMMUNE DISEASES; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; THYMUS GLAND; YELLOW FEVER VACCINE; YOUNG ADULT;

EID: 84908095859     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.051     Document Type: Review

References (42)

1. Vaccines 2012, 38:870-968. Saunders, China, Yellow fever vaccine. 6th ed.
2. Monath T.P. Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg 2010, 82(5):919-921.
3. Martin M., Tsai T.F., Cropp B., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001, 358(9276):98-104.
4. Vasconcelos P.F., Luna E.J., Galler R., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001, 358(9276):91-97.
5. Chan R.C., Penney D.J., Little D., Carter I.W., Roberts J.A., Rawlinson W.D. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001, 358(9276):121-122.
6. Thomas R.E., Lorenzetti D.L., Spragins W., Jackson D., Williamson T. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine 2011, 29(28):4544-4555.
7. Seligman S.J., Cohen J.E., Itan Y., Casanova J.L., Pezzullo J.C. Defining risk groups to yellow fever vaccine-associated viscerotropic disease in the absence of denominator data. Am J Trop Med Hyg 2014, 90(2):267-271.
8. Monath T.P. Dengue and yellow fever-challenges for the development and use of vaccines. N Engl J Med 2007, 357(22):2222-2225.
9. Monath T.P. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 2012, 11(4):427-448.
10. Staples J.E., Gershman M., Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59(RR-7):1-27.
11. Barwick R. History of thymoma and yellow fever vaccination. Lancet 2004, 364(9438):936.
12. Khromava A.Y., Eidex R.B., Weld L.H., et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005, 23(25):3256-3263.
13. Martin M., Weld L.H., Tsai T.F., et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001, 7(6):945-951.
14. Seligman S.J. Yellow fever virus vaccine-associated deaths in young women. Emerg Infect Dis 2011, 17(10):1891-1893.
15. Kengsakul K., Sathirapongsasuti K., Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 2002, 85(1):131-134.
16. Pacanowski J., Lacombe K., Campa P., et al. Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients. J Acquir Immune Defic Syndr 2012, 59(4):360-367.
17. Isenman H., Burns A. A case of yellow fever vaccine-associated disease. NZ Med J 2012, 125(1349):92-95.
18. Gershman M.D., Staples J.E., Bentsi-Enchill A.D., et al. Viscerotropic disease: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2012, 30(33):5038-5058.
19. Breugelmans J.G., Lewis R.F., Agbenu E., et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine 2013, 31(14):1819-1829.
20. Fitzner J., Coulibaly D., Kouadio D.E., et al. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan. Ivory Coast Vaccine 2004, 23(2):156-162.
21. Cottin P., Niedrig M., Domingo C. Safety profile of the yellow fever vaccine Stamaril(R): a 17-year review. Expert Rev Vaccines 2013, 12(11):1351-1368.
22. Werfel U., Popp W. Effects of yellow fever vaccination. Lancet 2001, 358(9296):1909.
23. Bae H.G., Domingo C., Tenorio A., et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis 2008, 197(11):1577-1584.
24. Rowland M., Plackett T.P., Smith R. Yellow fever vaccine-associated viscerotropic disease. Mil Med 2012, 177(4):467-469.
25. Lindsey N.P., Schroeder B.A., Miller E.R., et al. Adverse event reports following yellow fever vaccination. Vaccine 2008, 26(48):6077-6082.
26. Whittembury A., Ramirez G., Hernandez H., et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009, 27(43):5974-5981.
27. Monath T.P., Hayes E.B., Cetron M., Barrett A.D.T., Luna E. Serious events supposedly attributable to vaccination or immunization associated with receipt of yellow fever vaccine during a Mass Immunization Campaign Peru, 2007 2008, Pan American Health Organization, Washington, D.C.
28. de Menezes Martins R., de Lourdes de Sousa Maia, Matos dosSantos E., et al. Yellow fever vaccine post-marketing surveillance in Brazil. Procedia Vaccinol 2010, 2:178-183.
29. Sutton A.L., Smithwick E.M., Seligman S.J., Kim D.S. Fatal disseminated herpesvirus hominis type 2 infection in an adult with associated thymic dysplasia. Am J Med 1974, 56(4):545-553.
30. Belsher J.L., Gay P., Brinton M., et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 2007, 25(50):8480-8485.
31. Vaccines 2008, 36:959-1055. Saunders, China, Yellow fever vaccine. 5th ed.
32. Doblas A., Domingo C., Bae H.G., et al. Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol 2006, 36(2):156-158.
33. Puel A., Casanova J.L. Autoantibodies against cytokines: back to human genetics. Blood 2013, 121(8):1246-1247.
34. Poulin J.F., Viswanathan M.N., Harris J.M., et al. Direct evidence for thymic function in adult humans. J Exp Med 1999, 190(4):479-486.
35. Biscayart C., Carrega M.E., Sagradini S., et al. Yellow fever vaccine-associated adverse events following extensive immunization in Argentina (in press). Vaccine 2014.
36. Alcais A., Abel L., Casanova J.L. Human genetics of infectious diseases: between proof of principle and paradigm. J Clin Invest 2009, 119(9):2506-2514.
37. Casanova J.L., Abel L. The genetic theory of infectious diseases: a brief history and selected illustrations. Annu Rev Genomics Hum Genet 2013, 14:215-243.
38. Byun M., Abhyankar A., Lelarge V., et al. Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma. J Exp Med 2010, 207(11):2307-2312.
39. Pulendran B., Miller J., Querec T.D., et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008, 198(4):500-507.
40. Martinson J.J., Chapman N.H., Rees D.C., Liu Y.T., Clegg J.B. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997, 16(1):100-103.
41. Samson M., Libert F., Doranz B.J., et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382(6593):722-725.
42. Ling L.M., Wilder-Smith A., Leo Y.S. Fulminant hepatitis in dengue haemorrhagic fever. J Clin Virol 2007, 38(3):265-268.